Take a look at our previous reports:

Annual Report 2024

Oncology

Cancer affects us all, leaving no one untouched. The urgency for effective, broadly accessible treatment options is paramount, as many patients face a grim prognosis, with survival often measured in months rather than years. Advances in cancer research stand as a beacon of hope, offering the potential to transform patient outcomes.

At Galapagos, we are dedicated to redefining cancer treatment, striving to turn cancers into manageable chronic conditions, or even curable diseases. Our oncology researchers are committed to overcoming the devastating impact of cancer by accelerating novel approaches to targeting the disease from multiple angles. This includes pioneering next-generation therapies and breakthrough manufacturing technologies that enhance accessibility and efficacy.

We believe that the most transformative progress comes from combining cutting-edge science and technology, both within and beyond our organization, to establish a new, multi-faceted treatment paradigm for cancers with significant unmet medical needs.

We are advancing a broad cell therapy pipeline for multiple aggressive hematological and solid tumors, addressing patients in urgent need of better treatment options.

Our pipeline includes investigational therapies in more than 10 indications:

  • B-cell malignancies: clinical programs in mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)/follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), high-risk first-line DLBCL, Burkitt lymphoma (BL), primary CNS lymphoma (PCNSL), relapsed/refractory chronic lymphocytic leukemia (R/R CLL), Richter transformation (RT) of CLL and relapsed/refractory multiple myeloma (R/R MM) as well as early-stage programs in high unmet need indications.
  • Solid tumors: uza-cel, a TCR-T candidate for head and neck cancer, in partnership with Adaptimmune, and early-stage programs in additional indications of high unmet needs, including small cell lung cancer (SCLC), neuro-endocrine and ovarian cancer.

Looking ahead, we plan to initiate pivotal development of our most advanced program in 2026, targeting a first approval in 2028. Our early-stage pipeline is expected to generate at least one clinical candidate per year starting in 2026, reinforcing our commitment to continuous innovation and patient impact.

Burkitt lymphoma (BL)
BL is a rare, aggressive form of NHL that arises from B-lymphocytes, a type of white blood cells that produce antibodies. BL is the most common form of NHL in children, but it can also develop in adults. BL is more common in males than in females
Cell therapy
Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells)
Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia is the most common leukemia in adults. It is a type of cancer that starts in cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells originate in the bone marrow and migrate to the bloodstream
Efficacy
Effectiveness for intended use
Multiple myeloma (MM)
Multiple myeloma (MM) is typically characterized by the neoplastic proliferation of plasma cells producing a monoclonal immunoglobulin. The plasma cells proliferate in the bone marrow and can result in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or pathologic fractures
Oncology
Field of medicine that deal with the diagnosis, treatment, prevention, and early detection of cancer
Refractory
"Refractory" refers to a patient with cancer that is/has become resistant to, or does not respond to, treatment
Relapsed
"Relapsed" refers to a patient with cancer that develops cancer again after a period of improvement
Richter transformation
Richter transformation (RT) is an uncommon clinicopathological condition observed in patients with CLL. It is characterized by the sudden transformation of the CLL into a significantly more aggressive form of large cell lymphoma, and occurs in approximately 2-10% of all CLL patients